Frequency of homozygous deletion at p16/CDKN2 in primary human tumours

Nature Genetics - Tập 11 Số 2 - Trang 210-212 - 1995
Paul Cairns1, Thomas J. Polascik1, Yolanda Eby1, Kaori Tokino1, Joseph Califano1, Adrian Merlo1, Li Mao1, John F. Herath2, Robert P. Jenkins2, William H. Westra3, Joni L. Rutter4, Alan Buckler4, Edward Gabrielson3, Mel Tockman5, Kathleen R. Cho3, Lora Hedrick3, G. Steven Bova6, William Isaacs6, Wayne M. Koch1, Donna Schwab1, David Sidransky1
1Department of Otolaryngology Head and Neck Surgery, Head and Neck Cancer Research Division, Johns Hopkins University School of Medicine, 818 Ross Research Building, 720 Rutland Avenue, Baltimore, Maryland, 21205-2196, USA
2Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA
3Department of Pathology, Johns Hopkins Hospital, 600 N. Wolfe Street, Baltimore, MD, 21287, USA
4Massachusetts General Hospital & Harvard Medical School, Building 149, 13th Street, Charlestown, MA, 02129, USA
5Department of Environmental Health Sciences, Division of Occupational Health, Johns Hopkins University School of Hygiene and Public Health, Room 7515, 600 N. Wolfe Street, Baltimore, MD, 21205, USA
6Department of Urology, Johns Hopkins Hospital, 600 N. Wolfe Street, Baltimore, MD, 21287, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Diaz, M.O. et al. Deletions of interferon genes in acute lymphoblastic leukemia. N. Engl. J. Med. 332, 77–82 (1990).

Fountain, J.W. et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc. natn. Acad. Sci. U.S.A. 89, 10557–10561 (1992).

James, C.D. et al. Chromosome 9 deletion mapping reveals interferon a and interferon β-1 gene deletions in human glial tumors. Cancer Res. 51, 1684–1688 (1991).

Olopade, O.I. et al. Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res. 53, 2410–2415 (1993).

Cairns, P., Tokino, K., Eby, Y. & Sidransky, D. Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res. 54, 1422–1424 (1994).

van der Riet, P. et al. Frequent loss of chromosome 9p21 -22 early in head and neck cancer progression. Cancer Res. 54, 1156–1158 (1994).

Kamb, A. et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436–440 (1994).

Nobori, T. et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368, 753–756 (1994).

Knudson, A.G., Jr., Hethcote, H.W. & Brown, B.W. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc. natn. Acad. Sci. U.S.A. 72, 5116–5120 (1975).

Hussussian, C.J. et al. Germline p16 mutations in familial melanoma. Nature Genet. 8, 15–21 (1994).

Mori, T. et al. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) in esophageal squamous cell carcinoma. Cancer Res. 54, 3396–3397 (1994).

Caldas, C. et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 8, 27–32 (1994).

Hayashi, N., Sugimoto, Y., Tsuchiya, E., Ogawa, M. & Nakamura, Y. Somatic mutations of the MTS1 (multiple tumor suppressor) CDK41 (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem. biophys. Res. Commun. 202, 1426–1430 (1994).

Kamb, A. et al. Analysis of the p16 gene (CDKA/2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet. 8, 23–26 (1994).

Xu, L. et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res. 54, 5269–5272 (1994).

Zhou, X. et al. The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene 9, 3737–3747 (1994).

Okamoto, A. et al. Mutations in the p16(INK4)/MTS1/CDKN2,p15(INK4B)/ MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res. 55, 1448–1451 (1995).

Cairns, P. et al. Rates of p16(MTS1) mutations in primarytumors with 9p loss. Science 265, 415–416 (1994).

Xu, L., et al. Mutational analysis of CDKN2 (MTS1/P16INK4) in human breast carcinomas. Cancer Res. 54, 5262–5264 (1994).

Jen, J. et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res. 54, 6353–6358 (1994).

Middleton-Price, H., Spurr, N., Hall, A. & Malcolm, S. N-ras-like sequences on chromosomes 9,6 and 22 with a polymorphism at the chromosome 9 locus. Ann. hum. Genet. b, 189–195 (1988).

Sauter, G. et al. Chromosome-9 loss detected by fluorescence in situ hybridization in bladder cancer. Int. J. Cancer 64, 99–103 (1995).

Kamb, A., Liu, Q., Harshman, K. & Tavtigian, S. Rates of p16(MTS1) mutations in primary tumors with 9p loss. Science 265, 416–417 (1994).

Lefebvre, S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155–165 (1995).

Roy, N. et al. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 80, 167–178 (1995).

Cairns, P., Shaw, M.E. & Knowles, M.A. Initiation of bladder cancer may involve deletion of a tumor suppressor gene on chromosome 9. Oncogene 8, 1083–1085 (1993).

Merlo, A., et al. CpG island methylation is associated with transcriptional silencing of the tumour suppressor CDKN2/p16 in human cancers. Nature Med. 1, 686–692 (1995).

Weaver-Feldhaus, J. et al. Localization of a putative tumor suppressor gene by using homozygous deletions in melanomas. Proc. natn. Acad. Sci. U.S.A. 91, 7563–7567 (1994).

Zhang, J., Meltzer, P., Jenkins, R., Guan, X.Y., Trent, J. Application of chromosome microdissection probes for elucidation of BCR-ABL fusion and variant Philadelphia chromosome translocations in chronic myelogenous leukemia. Blood 81, (12), 3365–3371 (1993).

Thông tin
Thông tin xuất bản

Nature Genetics

Tập 11 Số 2

210-212

Thông tin tác giả